The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...
Chronic kidney disease (CKD) significantly amplifies cardiovascular (CV) risk, with CV disease remaining the leading cause of ...
Orlowski Calls Linvoseltamab Results “the Best Single Agent Data Ever In the History of Myeloma”
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
Chronic kidney disease (CKD) is a well-established risk factor for cardiovascular (CV) disease because declining kidney ...
FLAMeS, a new convolutional neural network, enhances MS lesion segmentation accuracy using only T2-weighted FLAIR images, ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...
These top 5 stories underscore how 2025 was a year of constant friction at the intersection of public health and political ...
Tom Kim, MD, of Sound Long-Term Care Management, discusses how serious illness and care coordination set these ACO patients ...
Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...
Panelists discuss how schizophrenia typically evolves through distinct phases—from first-episode psychosis to chronic illness ...
New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback